Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) saw unusually-high trading volume on Tuesday . Approximately 189,901 shares traded hands during mid-day trading, an increase of 24% from the previous session’s volume of 153,480 shares.The stock last traded at $7.32 and had previously closed at $7.80.

ADAP has been the topic of several research analyst reports. Leerink Swann decreased their price target on shares of Adaptimmune Therapeutics PLC – from $24.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, March 29th. Zacks Investment Research raised Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research note on Tuesday, July 12th. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $15.94.

The company’s 50-day moving average price is $9.09 and its 200-day moving average price is $8.78. The stock’s market cap is $518.85 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last posted its earnings results on Thursday, May 12th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.03. Equities analysts forecast that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current year.

In other Adaptimmune Therapeutics PLC – news, Director Charles Elliott Sigal purchased 45,000 shares of the company’s stock in a transaction dated Wednesday, May 18th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $68,850.00. Following the purchase, the director now directly owns 52,938 shares of the company’s stock, valued at approximately $80,995.14. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc purchased 1,712,400 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were acquired at an average price of $10.42 per share, for a total transaction of $17,843,208.00. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of Adaptimmune Therapeutics PLC – during the fourth quarter valued at $1,700,000. Tekla Capital Management LLC boosted its position in Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock worth $3,581,000 after buying an additional 15,000 shares during the period. Finally, Jennison Associates LLC boosted its position in Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock worth $5,873,000 after buying an additional 1,547 shares during the period.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.